FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average bu	rden									
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Slager David Mark (Last) (First) (Middle)							2. Issuer Name and Ticker or Trading Symbol ORAMED PHARMACEUTICALS INC. [ORMP] 3. Date of Earliest Transaction (Month/Day/Year) 10/31/2017								5. Relationship of Reporting Person(s) to Issuer Check all applicable) X Director 10% Owner Officer (give title below) below)			
152 WEST 57TH STREET, 9TH FLOOR (Street) NEW YORK NY 10019						4. If Amendment, Date of Original Filed (Month/Day/Year)								dividual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(5)		Zip)															
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transactio Date (Month/Day/Y					ion 2 (/Year) i	2A. Deemed Execution Date,			3. 4. Securiti		es Acquired (A) or Of (D) (Instr. 3, 4 and		5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	ľ	Amount	(A) or (D)	Price	Transact (Instr. 3	tion(s)			
Common Stock 10/31/201						17			M		16,892	A	\$3.7650	5 1,310	6,328		I ⁽¹⁾	By Regals Fund LP
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution Dear) if any		4. Transac Code (In 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Expiration D (Month/Day/		ate	7. Title a Amount Securitie Underlyi Derivativ Security and 4)	of s ng e (Instr. 3	8. Price of Derivative Security (Instr. 5)	9. Numb derivativ Securitie Beneficia Owned Followin Reported Transact (Instr. 4)	e s ally g	10. Ownership Form: Direct (D) or Indirec (I) (Instr. 4)	Beneficial Ownership
					Code	v	(A)	(D)	Date Exercis	sable	Expiration Date	Title	or Number of Shares					
Warrant (right to buy)	\$3.7656	10/31/2017			М			16,892 ⁽²⁾	11/05/2	2012	11/05/2017	Common Stock	16,892	\$1.1796 ⁽³⁾	0		I	By Regals Fund LP

Explanation of Responses:

- 1. Mr. Slager is Managing Member of the general partner of Regals Capital Management LP ("Regals Management"). Regals Management is the investment manager of Regals Fund LP (the "Fund"). The securities reported herein are held for the account of the Fund. Pursuant to Rule 16a-1(a)(4) under the Act, Mr. Slager disclaims beneficial ownership in the securities owned by the Fund except to the extent, if any, of his pecuniary interest therein.
- 2. The number of shares underlying such warrant and the applicable exercise price reflect a one-for-twelve reverse stock split effected by the issuer on January 22, 2013.
- 3. The shares and warrants were purchased as "units" at a price per unit of \$4.44 in connection with the Issuer's 2012 private placement. The consideration was allocated to the shares and warrants based on relative fair value. The value allocated to the warrants was estimated by using the Black Scholes option-pricing model.

<u>/s/ David Slager</u> <u>11/01/2017</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.